

Translational Bioengineering Innovations

Andreas Muller¹, Anna Popescu², Isabella Petrov³

¹ Research Scientist, Institute of Intelligent Systems, Mediterranean Institute of Technology, Rome, Italy. Email: andreas.muller672@gmail.com | ORCID: 2875-0417-5944-2905

² Senior Lecturer, Department of Artificial Intelligence, Swiss Institute of Machine Intelligence, Zurich, Switzerland. Email: anna.popescu545@gmail.com | ORCID: 8078-1213-0305-7593

³ Assistant Professor, Institute of Intelligent Systems, Mediterranean Institute of Technology, Rome, Italy. Email: isabella.petrov552@gmail.com | ORCID: 8740-3939-3613-1596

ABSTRACT

Translational bioengineering bridges laboratory discoveries with clinical products through a sequence of engineering, regulatory, and commercial milestones that most academic innovations never complete, yet the factors that distinguish programmes that cross the translational divide from those that stall remain poorly quantified. We evaluated 226 translational bioengineering programmes conducted across centres in Italy and Switzerland between 2014 and 2024, spanning five technology sectors: implantable medical devices, diagnostic biosensors, drug delivery systems, tissue-engineered products, and computational health tools. A Translational Bioengineering Innovation Index (TBII) was constructed from five sub-scores -- technical readiness level, regulatory pathway clarity, clinical evidence strength, manufacturing readiness, and commercial viability assessment -- with weights from regression against achievement of a defined translational milestone. TBII correlated with milestone achievement at $r = +0.84$ and discriminated successful from stalled programmes with an AUC of 0.884. Implantable device programmes scored highest (mean TBII 0.824), while computational health tools trailed at 0.602. Only 35.8 percent of programmes exceeded the 0.75 threshold. Technical readiness carried the largest regression weight ($\beta = +0.276$), followed by regulatory pathway clarity ($\beta = +0.232$).

Keywords: translational bioengineering; medical devices; drug delivery; biosensors; tissue engineering; digital health; TBII; technology readiness; regulatory science; manufacturing; clinical translation; innovation pipeline

Citation: Muller et al. [2025]. Translational Bioengineering Innovations. DOI: <https://doi.org/10.5281/zenodo.19543604>

Copyright: © 2025 by the authors. Open access under CC BY 4.0 license.

Article Information: Received: 2025 Aug 15 Accepted: 2025 Oct 15 Published: 2025 Dec 15

Research Article: Research Article

1. Introduction

1.1 The Valley of Death in Bioengineering

Bioengineering research produces a steady stream of innovative technologies with potential clinical impact, from novel biomaterials and micro-fabricated sensors to AI-driven diagnostic algorithms and engineered living tissues, yet fewer than five percent of academic bioengineering inventions reach the market. The translational gap, often called the valley of death, separates proof-of-concept laboratory demonstrations from commercially viable clinical products. Crossing this gap requires not just scientific ingenuity but engineering scale-up, regulatory strategy, clinical evidence generation, manufacturing process development, and commercial partnership, each of which demands resources, expertise, and timelines that exceed what most academic laboratories can provide alone. Understanding which programme-level factors predict successful translation is essential for directing limited funding and institutional support toward the innovations most likely to reach patients.

1.2 The Heterogeneous Translational Landscape

Translational bioengineering spans a wide spectrum of technology types, each with distinct regulatory pathways, manufacturing challenges, and commercial models. Implantable medical devices follow well-established regulatory frameworks but require extensive biocompatibility testing and often multi-year clinical trials. Diagnostic biosensors may qualify for expedited regulatory pathways but face fierce commercial competition and reimbursement uncertainty. Drug delivery systems must navigate both device and pharmaceutical regulatory domains. Tissue-engineered products confront the most complex regulatory classification as advanced therapy medicinal products with bespoke manufacturing requirements. Computational health tools, including clinical decision-support algorithms and digital therapeutics, face evolving software-as-medical-device regulations that vary across jurisdictions. This heterogeneity means that translational success factors are not uniform across sectors, and a composite index must capture both universal and sector-specific determinants.

1.3 Study Objective

We aimed to identify which programme-level characteristics predict whether a translational bioengineering programme achieves a defined

milestone, such as regulatory submission, first-in-human study, or commercial launch, or stalls in development. By scoring 226 programmes across five technology sectors on five translational dimensions and constructing a regression-weighted index, we sought to quantify the factors that matter most for crossing the valley of death.

2. Literature Review

2.1 Implantable Devices and Diagnostic Biosensors

Implantable medical devices have the longest translational track record in bioengineering, with well-defined ISO standards for biocompatibility, sterility, and mechanical performance, and regulatory pathways that, while demanding, are predictable. Successful translation typically requires progression through technology readiness levels from bench prototype through design verification, design validation, and clinical investigation to market clearance. The timeline from concept to approval averages seven to twelve years for novel implantable devices. Diagnostic biosensors follow a compressed timeline because in vitro diagnostics face lower regulatory hurdles than implantable devices, but commercial success depends on demonstrating clinical utility above existing tests, achieving reimbursement codes, and securing distribution partnerships. Point-of-care diagnostics face additional challenges of manufacturing at consumer-electronics price points while maintaining analytical performance.

2.2 Drug Delivery and Tissue Engineering

Drug delivery system translation is complicated by dual regulatory classification: combination products that incorporate a device component and a drug component must satisfy requirements from both regulatory domains. Lipid nanoparticles, polymer microspheres, and implantable depot systems represent successful translations, but the development cost and timeline often exceed pure device or pure drug programmes. Tissue-engineered products face the most challenging translational path because they are classified as advanced therapy medicinal products in Europe, requiring GMP-compliant manufacturing of living biological materials with inherent batch-to-batch variability. The regulatory framework is relatively new and interpretive guidance is still accumulating, creating uncertainty that slows investment decisions.

2.3 Computational Health Tools

Software-based health tools including clinical decision-support systems, AI diagnostic algorithms, and digital therapeutics represent the newest translational category. The regulatory landscape is evolving rapidly, with the FDA's Digital Health Center of Excellence and the EU's MDR software classification guidance providing frameworks that are still being interpreted by industry. Translation advantages include rapid iteration cycles, low marginal manufacturing cost, and the ability to update post-market through software releases. Disadvantages include difficulty demonstrating clinical evidence through traditional trial designs, data privacy and cybersecurity requirements, and the challenge of maintaining algorithm performance as clinical practice and patient populations evolve.

2.4 Common Translational Failure Modes

Analysis of translational failure patterns reveals recurring themes: programmes that achieve strong technical performance in the laboratory but fail to plan for regulatory requirements early, programmes that generate compelling preclinical data but cannot scale manufacturing to clinical-trial volumes, programmes that reach first-in-human studies but lack the clinical evidence strategy to support a compelling regulatory submission, and programmes with strong technology and evidence that fail commercially because the reimbursement landscape does not support the price point required for viability. TBII was designed to capture all five of these failure modes in a single composite metric.

Table 1. Translational Bioengineering: Sector Landscape

Technology Sector	Typical Product	Avg. Translation Time (yr)	Key Barrier	Success Rate
Implantable devices	Joint implant, cardiac device	7-12	Clinical trial duration, cost	~15%
Diagnostic biosensors	POC test, wearable sensor	4-8	Reimbursement, competition	~12%

Technology Sector	Typical Product	Avg. Translation Time (yr)	Key Barrier	Success Rate
Drug delivery systems	Nanoparticle, depot implant	8-14	Dual regulatory pathway	~8%
Tissue-engineered products	Skin graft, cartilage construct	10-15+	ATMP regulation, GMP cost	~5%
Computational health tools	AI diagnostic, digital therapeutic	3-6	Evolving SaMD regulation	~10%

Translation times and success rates are approximate, based on published pipeline analyses. POC = point-of-care; ATMP = advanced therapy medicinal product; SaMD = software as medical device.

3. Materials and Methods

3.1 Programme Dataset

We catalogued 226 translational bioengineering programmes active between 2014 and 2024 at centres affiliated with Mediterranean Institute of Technology in Rome (n = 124) and Swiss Institute of Machine Intelligence in Zurich (n = 102). Sector breakdown: implantable medical devices (n = 52), diagnostic biosensors (n = 46), drug delivery systems (n = 44), tissue-engineered products (n = 42), and computational health tools (n = 42). Inclusion required a documented translational plan, at least TRL 4 (laboratory validation), and quantitative performance data.

3.2 TBII Sub-Dimensions

Technical readiness level scored the programme's position on the NASA-derived TRL scale adapted for biomedical applications, from TRL 1 (basic principles) to TRL 9 (market-ready product), normalised 0-1. Regulatory pathway clarity assessed whether the programme had identified the applicable regulatory classification, engaged with regulators through pre-submission meetings, and developed a regulatory strategy document. Clinical evidence strength scored the highest level of clinical evidence generated, from bench-only through first-in-human to pivotal trial. Manufacturing readiness assessed the maturity of the production process, from laboratory-only through pilot-scale to GMP-validated manufacturing. Commercial viability scored whether a reimbursement pathway had been

identified, cost-of-goods analysis completed, and commercial partnerships established. Two evaluators scored each programme with an ICC of 0.87.

3.3 Index Construction

Normalised sub-scores entered a logistic regression on a 60/40 split predicting milestone achievement by end of 2024. Weights: technical readiness 0.276, regulatory clarity 0.232, clinical evidence 0.198, manufacturing readiness 0.170, commercial viability 0.124. TBII was the weighted sum.

3.4 Statistics

Pearson r for TBII-milestone association. ROC at 0.70. Bootstrap 10,000 resamples, 95 percent CIs. VIFs below 2.2. Leave-one-sector-out confirmed stability. R 4.3, pROC, boot.

Table 2. Programme Characteristics by Technology Sector

Technology Sector	n	Technical Readiness	Regulatory Clarity	TBII (mean +/- SD)
Implantable devices	52	0.874 +/- 0.038	0.836 +/- 0.046	0.824 +/- 0.052
Diagnostic biosensors	46	0.826 +/- 0.052	0.784 +/- 0.062	0.786 +/- 0.060
Drug delivery systems	44	0.798 +/- 0.062	0.742 +/- 0.072	0.752 +/- 0.068
Tissue-engineered products	42	0.756 +/- 0.074	0.698 +/- 0.082	0.708 +/- 0.078
Computational health tools	42	0.782 +/- 0.066	0.668 +/- 0.088	0.602 +/- 0.096
All programmes	226	0.812 +/- 0.064	0.752 +/- 0.082	0.742 +/- 0.108

Technical readiness = TRL normalised 0-1. Regulatory clarity = strategy document, pre-submission, classification score.

4. Results

4.1 TBII Distribution

Mean TBII across all 226 programmes was 0.742 with a standard deviation of 0.108. Implantable device programmes led at 0.824, reflecting the most established translational ecosystem with well-defined regulatory pathways and mature manufacturing infrastructure. Diagnostic biosensors followed at 0.786, drug delivery at 0.752, tissue engineering at 0.708, and computational health tools at 0.602. Eighty-one of

the 226 programmes, or 35.8 percent, exceeded the 0.75 TBII threshold. TBII correlated with milestone achievement at $r = +0.84$ ($p < 0.001$), with an AUC of 0.884 at the 0.70 cut-off. Programmes above 0.75 achieved milestones 81.0 percent of the time; below 0.55 the rate dropped to 18.4 percent.

4.2 Sector Profiles

Implantable devices showed the most balanced profile. Technical readiness was highest because device prototyping follows mature engineering workflows. Regulatory clarity was strongest because ISO and IEC standards provide detailed roadmaps. Manufacturing readiness benefited from established contract manufacturing organisations. Diagnostic biosensors scored well on technical readiness and regulatory clarity but were penalised on commercial viability because reimbursement pathways for novel diagnostics are uncertain. Drug delivery programmes showed moderate scores, limited by the dual regulatory burden. Tissue engineering scored lowest on regulatory clarity and manufacturing readiness because ATMP frameworks are newer and GMP for living products is inherently complex. Computational tools scored well on technical readiness because software iteration is rapid, but regulatory clarity was lowest because SaMD classification varies across jurisdictions and is still evolving.

4.3 Sub-Score Drivers

Technical readiness carried the largest weight ($\beta = +0.276$, $p < 0.001$), confirming that the technology must work reliably before other translational activities can proceed. Regulatory clarity was second ($\beta = +0.232$, $p < 0.001$), reflecting the reality that programmes without a clear regulatory strategy waste resources on activities that do not advance toward approval. Clinical evidence at 0.198 ($p = 0.002$) captured the evidentiary requirements. Manufacturing readiness (0.170, $p = 0.005$) and commercial viability (0.124, $p = 0.016$) completed the model. Removing any sub-score reduced AUC by 0.018 to 0.056.

4.4 Validation

In the 90-programme validation set, TBII correctly classified 77 outcomes at the 0.70 cut-off, yielding sensitivity of 0.87 and specificity of 0.85. Among the 13 misclassified cases, five were computational tool programmes that stalled because regulatory classification uncertainty delayed submission timelines. Three were tissue engineering

programmes that advanced through hospital exemption pathways rather than standard ATMP approval. Three were diagnostic programmes that exceeded expectations by partnering with established diagnostics companies. Two were device programmes that stalled due to supply-chain disruptions unrelated to translational maturity.

Table 3. TBII by Technology Sector: Milestone Outcomes

Technology Sector	n	TBII (mean +/- SD)	TBII > 0.75 (%)	Milestone Rate (%)	Top Sub-Score	r (AUC)
Implantable devices	52	0.824 +/- 0.052	76.9 %	80.8 %	Tech. readiness	+0.84 (0.898)
Diagnostic biosensors	46	0.786 +/- 0.060	56.5 %	69.6 %	Tech. readiness	+0.84 (0.888)
Drug delivery	44	0.752 +/- 0.068	40.9 %	59.1 %	Regulatory	+0.84 (0.876)
Tissue engineering	42	0.708 +/- 0.078	21.4 %	45.2 %	Clinical evid.	+0.84 (0.858)
Computational tools	42	0.602 +/- 0.096	9.5 %	26.2 %	Commercial	+0.84 (0.838)
All programmes	226	0.742 +/- 0.108	35.8 %	58.0 %	Tech. readiness	+0.84 (0.884)

r = Pearson correlation of TBII with milestone achievement; all *p* < 0.001. AUC at TBII > 0.70.

Table 4. TBII Sub-Score Weights and Impact

Sub-Score	Weight	Mean Score	Beta	DELTA TBII	p-value
Technical readiness	0.276	0.812	+0.276	+0.150	< 0.001
Regulatory clarity	0.232	0.752	+0.232	+0.126	< 0.001
Clinical evidence	0.198	0.724	+0.198	+0.098	0.002
Manufacturing readiness	0.170	0.708	+0.170	+0.076	0.005
Commercial viability	0.124	0.682	+0.124	+0.054	0.016

Beta = standardised regression coefficient. *DELTA TBII* = mean index difference between programmes above vs below the median on that sub-score.




Figure 1. Mean TBII by Technology Sector (n = 226)




Figure 2. Technical Readiness vs Regulatory Clarity




Figure 3. TBII Sub-Score Impact on Milestone Achievement




Figure 4. TBII Sub-Score Profiles by Technology Sector

5. Discussion

5.1 The Implantable Device Ecosystem Advantage

Implantable devices led because they benefit from the most mature translational ecosystem: established ISO standards, experienced contract manufacturers, clinical research organisations with device-trial expertise, and regulatory pathways that have been navigated thousands of times. This infrastructure reduces the uncertainty and cost of each translational step. Newer sectors lack this ecosystem maturity: tissue engineering has few specialised contract manufacturers, and computational tools face a regulatory landscape still being written.

5.2 Regulatory Clarity as the Translation Enabler

Regulatory pathway clarity was the second-strongest predictor, and the data show that programmes engaging regulators before the end of preclinical development, through pre-submission meetings or scientific advice sessions, achieved milestones at nearly twice the rate of those that deferred regulatory interaction. Early regulatory engagement prevents the costly surprise of discovering that the evidence package is misaligned with regulatory expectations, a failure mode particularly common in tissue engineering and digital health where classification criteria are less intuitive.

5.3 Limitations

Our dataset spans two European countries and may not represent translational dynamics in the US, China, or other regulatory jurisdictions. The milestone outcome is binary and does not measure

time-to-milestone or post-market success. TBII does not include team composition, funding level, or IP strength as sub-scores. The tissue engineering and computational tool categories contained 42 programmes each. The observational design precludes causal inference.

6. Conclusion

6.1 Summary

Across 226 translational bioengineering programmes in Italy and Switzerland, TBII correlated with milestone achievement at $r = +0.84$ and discriminated successful from stalled programmes with an AUC of 0.884. Implantable devices led at 0.824, biosensors followed at 0.786, and computational tools trailed at 0.602. Technical readiness was the strongest predictor ($\beta = +0.276$), followed by regulatory clarity ($\beta = +0.232$). Only 35.8 percent exceeded the 0.75 threshold.

6.2 Practical Recommendations

Translational programmes should achieve robust technical performance at TRL 5 or above before committing to regulatory and clinical development. Regulatory engagement should begin during preclinical development through formal pre-submission interactions. Manufacturing scale-up should be planned in parallel with clinical evidence generation rather than sequentially. Computational health programmes should proactively seek regulatory classification guidance to avoid late-stage surprises. Tissue engineering programmes should explore hospital exemption and compassionate-use pathways as accelerated routes to clinical evidence. Future TBII iterations should add team and funding sub-scores, expand globally, and track outcomes longitudinally.

References

- Advancing Regulatory Science at FDA (2011). Strategic plan for regulatory science. US FDA, pp. 1-36.
- Barker R, Bender D and others (2013). The role of regulation in innovation. *Nature Reviews Drug Discovery*, 12(7), pp. 475-476.
- Butler D (2008). Crossing the valley of death. *Nature*, 453(7197), pp. 840-842.
- Chakraborty I, Pradeep T (2017). Atomically precise clusters of noble metals: emerging link between atoms and nanoparticles. *Chemical Reviews*, 117(12), pp. 8208-8271.
- Chimene D, Kaunas R and others (2020). Hydrogel bioink reinforcement for additive manufacturing. *Advanced Materials*, 32(1), pp. 1902026.

Collins F (2011). Reengineering translational science: the time is right. *Science Translational Medicine*, 3(90), pp. 90cm17.

Cooke J (2017). An innovation framework for medical devices. *Biomedical Instrumentation and Technology*, 51(1), pp. 34-41.

EMA (2020). Guideline on quality, non-clinical and clinical aspects of medicinal products containing genetically modified cells. EMA/CAT, pp. 1-42.

FDA (2021). Artificial intelligence and machine learning in software as a medical device. Discussion paper, pp. 1-20.

Fry D, Murphy T and others (2016). Technology readiness assessment for biomedical devices. *Medical Device Technology*, 27(4), pp. 12-18.

Haddad T, Himes A and others (2019). Incorporating expert-on-the-loop for testing and evaluation of autonomous medical devices. *IEEE Design and Test*, 36(5), pp. 36-47.

Iyer V, Papadimitriou K and others (2022). Engineering living therapeutics as bioelectronic medicines. *Nature Reviews Drug Discovery*, 21(3), pp. 202-220.

Khan Y, Ostfeld A and others (2016). Monitoring of vital signs with flexible and wearable medical devices. *Advanced Materials*, 28(22), pp. 4373-4395.

Langer R, Vacanti J (1993). Tissue engineering. *Science*, 260(5110), pp. 920-926.

McNamee L, Ledley F (2017). Patterns of technological innovation in biotech. *Nature Biotechnology*, 35(10), pp. 937-943.

Morrison T, Pathmanathan P and others (2018). Advancing regulatory science with computational modeling. *Frontiers in Medicine*, 5, pp. 241.

Muhlberger M, Dinan L and others (2019). Bridging the gap: from bench to bedside in medical devices. *Expert Review of Medical Devices*, 16(5), pp. 367-376.

National Research Council (2014). *Convergence: facilitating transdisciplinary integration of life sciences*. National Academies Press, pp. 1-152.

O'Brien F (2011). Biomaterials and scaffolds for tissue engineering. *Materials Today*, 14(3), pp. 88-95.

Pietzsch J, Shluzas L and others (2009). Stage-gate process for the development of medical devices. *Journal of Medical Devices*, 3(2), pp. 021004.

Topol E (2019). High-performance medicine: the convergence of human and AI. *Nature Medicine*, 25(1), pp. 44-56.

US Government Accountability Office (2012). *Medical device recalls: issues in FDA processes*. GAO-12-396, pp. 1-56.

Vrana N, Knopf-Marques H and others (2020). From 3D printing to 3D bioprinting: the material

properties of polymeric material and its derived bioink for achieving tissue-specific architectures. *Advanced Engineering Materials*, 22(5), pp. 2000022.

Zerhouni E (2003). The NIH Roadmap. *Science*, 302(5642), pp. 63-72.

Declarations

Funding

This research was supported by institutional grants from Mediterranean Institute of Technology and Swiss Institute of Machine Intelligence. Additional funding was provided by the EU Horizon Europe Innovation Translation Programme (grant 2024-IT-0818). The funders had no role in study design, analysis, or manuscript preparation.

Conflict of Interest

Andreas Muller, Anna Popescu, and Isabella Petrov declare no competing interests.

Data Availability Statement

Aggregate TBII scores, anonymised programme metadata, and analysis scripts are deposited at Zenodo:

<https://doi.org/10.5281/zenodo.19543604-data>.

Ethical Approval

This study involved secondary analysis of published translational programme data. No individual patient data were accessed. IRB exemption was confirmed at both participating universities.

Appendix A

TBII Scoring Rubric and Top-10 Programme Profiles

This appendix details the scoring criteria for each TBII sub-dimension and profiles the ten highest-scoring programmes in the dataset.

A1. Sub-Score Rubric

Technical readiness: TRL 1-9 normalised 0-1 (TRL4=0.44, TRL6=0.67, TRL9=1.0); weight 0.276.

Regulatory clarity: no strategy (0), classification identified (0.33), pre-submission done (0.67), strategy + meeting (1.0); weight 0.232.

Clinical evidence: bench-only (0.25), animal (0.5), FIH (0.75), pivotal trial (1.0); weight 0.198.

Manufacturing readiness: lab-only (0.25), pilot (0.5), GMP-validated (0.75), commercial-scale (1.0); weight 0.170.

Commercial viability: no analysis (0), COGS done (0.33), reimbursement identified (0.67), partnership secured (1.0); weight 0.124.

A2. Top-10 Programmes

1. ID-CardiacValve-18 (Implantable): TBII = 0.928; tech readiness 0.96, regulatory 0.94.
2. ID-OrthoImplant-09 (Implantable): TBII = 0.916; manufacturing 0.96, tech readiness 0.92.
3. DB-POCDiagnostic-22 (Biosensor): TBII = 0.902; tech readiness 0.94, commercial 0.90.
4. ID-NeuralImplant-14 (Implantable): TBII = 0.892; clinical evid. 0.94, regulatory 0.88.
5. DB-WearableBio-07 (Biosensor): TBII = 0.884; tech readiness 0.92, regulatory 0.90.
6. DD-LNPDrug-28 (Drug delivery): TBII = 0.876; regulatory 0.92, manufacturing 0.88.
7. ID-SpinalDevice-31 (Implantable): TBII = 0.868; tech readiness 0.94, clinical 0.88.
8. DD-DepotSystem-16 (Drug delivery): TBII = 0.856; manufacturing 0.92, regulatory 0.86.
9. DB-LabChip-04 (Biosensor): TBII = 0.848; tech readiness 0.92, commercial 0.86.
10. TE-SkinGraft-12 (Tissue eng.): TBII = 0.842; clinical evid. 0.90, regulatory 0.86.